OP13.06: StopPRE trial: effect of aspirin discontinuation at 24–28 weeks on the trajectories of biophysical and biochemical markers

Documenti analoghi

• Role of routine uterine artery Doppler at 18–22 and 24–28 weeks' gestation following routine first‐trimester screening for pre‐eclampsia
  di: E. Bonacina, et al.
  Pubblicazione: (2024)
• Cost–benefit analysis of first‐trimester pre‐eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor
  di: E. Bonacina, et al.
  Pubblicazione: (2026)
• Placental insufficiency markers to assess the risk of non‐chromosomal genetic conditions in early‐onset fetal growth restriction
  di: M. Armengol‐Alsina, et al.
  Pubblicazione: (2026)
• Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early‐onset small fetuses with and without pre‐eclampsia
  di: E. Bonacina, et al.
  Pubblicazione: (2026)
• EP17.15: Evaluation of clinical and biophysical markers as a screening test for late‐onset pre‐eclampsia between 35 and 38 weeks of gestation
  di: M. Parra‐Cordero, et al.
  Pubblicazione: (2024)